Literature DB >> 6995040

Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects.

I Kass, T S Mingo.   

Abstract

Bitolterol mesylate (WIN 37284) is alpha-[tert-butylaminomethyl]-3,4-dihydroxybenzyl alcohol 3,4-di(p-toluate) methanesulfonate, a diester sympathomimetic amine bronchodilator. Bitolterol mesylate represents a new concept in sympathomimetic amine therapy. It is "prodrug" which is inactive until altered in the body. The intact 3,4-diester molecule is metabolized by esterase hydrolysis to release the active catecholamine, N-t-butylarterenol. Because the level of esterase is greater in the pulmonary tissue than in the heart, bitolterol mesylate aerosol was shown to be an effective bronchodilator drug, without any significant cardic side effects. The onset of action was rapid and lasted more than six hours. The improvement over baseline values in the forced expiratory volume in the first second and the mean forced expiratory flow during the middle half of the forced vital capacity was greater than 15 percent and 30 percent, respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995040     DOI: 10.1378/chest.78.2.283

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs.

Authors:  L A Svensson
Journal:  Pharm Res       Date:  1985-07       Impact factor: 4.200

2.  Prodrugs and outpatient medical practice.

Authors:  C Scoggin
Journal:  Bull N Y Acad Med       Date:  1983-06

Review 3.  Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.